Breaks Categories: News

MondayMar 01, 2021 12:07 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Update on Promotional and Marketing Activity Comments

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has provided an update to its Jan. 22, 2021, press release regarding recent promotional and investor relations. The updated comments were made at the request of IIROC and the Canadian Securities Exchange ("CSE"). The comments are specifically in regard to a newsletter published by WallStreetAlerts, on behalf of the company. In addition to the updated comments, the company reminded investors that the best source for full disclosure about the company is the company itself, as well as SEDAR…

Continue Reading

MondayMar 01, 2021 10:39 am

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Results of Annual and Special Meeting

PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has released results of its recent annual and special shareholder meeting. The meeting was held Feb. 26, 2021, and during the meeting, shareholders nominated and elected five board members: Quinn Field-Dyte, Lorne Rapkin, Peter Simeon, Alex Hoffman and Ralph Moxness. The company noted that incumbent director Todd Shapiro did not seek re-election at the meeting. Alex Hoffman and Ralph Moxness were elected to the board of directors for the first time. During the course of the meeting, shareholders passed all other motions on the agenda, including fixing the number of directors of…

Continue Reading

MondayMar 01, 2021 9:26 am

BioMedNewsBreaks – Grey Cloak Tech Inc. (GRCK) Changes Name, Ticker; Now Healthy Extracts Inc.

Grey Cloak Tech (OTCQB: GRCK) has announced that the company has officially changed its name to Healthy Extracts Inc. The company’s ticker will also change to OTCQB: HYEX. These changes are official today, March 1, 2021. The company is focused on the development of its proprietary natural plant-based formulations; the company is also committed to sales and distribution of cardiovascular and neuro products. Grey Cloak, now Healthy Extracts, has two subsidiaries: Ultimate Brain Nutrients, a science-based company that develops unique, plant-based, high-quality, neuro-products that increase brain health including memory, cognition, focus and neuro-energy; and BergaMet NA, a provider of nutraceutical…

Continue Reading

ThursdayFeb 25, 2021 1:00 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Progress Toward Upcoming Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today confirmed that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier and is in development for the treatment of a number of serious brain and CNS oncology indications. The upcoming, potentially pivotal study will evaluate the efficacy of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”), one of…

Continue Reading

WednesdayFeb 24, 2021 10:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into an agreement for WPD to obtain Investigational Medicinal Product (“IMP”) classification for Berubicin for its use in upcoming  clinical trials. According to the update, WPD will purchase half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies, planned to begin in the first half of 2021. Berubicin is a novel anthracycline candidate for the treatment of a number…

Continue Reading

WednesdayFeb 24, 2021 10:15 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Announces Receipt of Regulatory Approval Powdery Mildew Bio-Fungicide in Canada

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has received regulatory approval from Canada’s Pest Management Regulatory Agency (“PMRA”) for use of a powdery mildew bio-fungicide product; the approval covers use of the powdery mildew bio-fungicide suppression treatment on cannabis and hemp products. MustGrow announced more than a year ago that it had completed a definitive licensing agreement to obtain the exclusive treatment from a leading multinational biological and microbial company. The bio-fungicide product, which is not mustard derived, like MustGrow’s other products, is designed to…

Continue Reading

WednesdayFeb 24, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as COVID-ID Labs, were ordered from XPhyto’s exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order consists of 9,600 individual tests; the tests are packaged in 200 kits of 48 tests each. The tests, which should arrive by mid-March 2021, will be used as samples for review and evaluation and will be primarily given to prospective distribution partners and licensees…

Continue Reading

WednesdayFeb 24, 2021 9:45 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Borkowski will remain as lead independent director of the board of directors. “Having served on AzurRx’s board since 2015, I am committed to ensuring a prosperous future for the company,” said Borkowski. “Under James’ leadership, AzurRx has strategically expanded…

Continue Reading

WednesdayFeb 24, 2021 9:32 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no more than 4,521,883 shares of common stock in the private placement. The common stock and associated warrants were issued for $1.95 each, with the warrants having an exercise price of $2 per share. The shares are exercisable immediately; however, they do have a five and…

Continue Reading

TuesdayFeb 23, 2021 10:12 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Present at Cowen 41st Annual Health Care Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics (“DTx”) market, today announced the company’s plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. According to the update, Dario's CEO, Erez Raphael and Rick Anderson, president and general manager for North America, are scheduled to present in a virtual setting at 11:00 a.m. ET on Monday, March 1, 2021. Interested parties can access the live and archived webcast via the company’s website. To view the full press release, visit https://ibn.fm/nac7n About DarioHealth Corp. DarioHealth is a leading, global digital-therapeutics…

Continue Reading